SGLT2 Inhibitors

SGLT2 inhibitors represent a class of diabetes medications that studies suggest may offer benefits extending beyond blood sugar control. Originally developed for type 2 diabetes management, research indicates these drugs may provide significant cardiovascular and kidney protection. Major clinical trials have demonstrated reduced risk of heart failure hospitalization, cardiovascular death, and progression of chronic kidney disease, leading to expanded therapeutic indications.

The mechanism involves blocking glucose reabsorption in the kidneys, resulting in glucose excretion through urine. Research suggests this approach may improve cardiac metabolism, reduce blood pressure modestly, and promote weight loss of 2-4 kg on average. Studies indicate the cardiovascular benefits may occur independently of glucose-lowering effects, suggesting additional protective mechanisms.

While generally well-tolerated, studies report potential risks including genital infections, urinary tract infections, and rare cases of diabetic ketoacidosis. Research indicates increased risk of dehydration and acute kidney injury, particularly in elderly patients or those taking diuretics. The growing body of evidence supporting cardiovascular and kidney benefits has made these medications increasingly relevant for longevity-focused approaches, though they remain prescription medications requiring medical supervision.